https://www.selleckchem.com/pr....oducts/Aloxistatin.h
14%) underwent TAVR. One-third of enrolled patients were female, and the majority of the patients were White with a mean age of 65.9 ± 15.1 years. TAVR use for BAV stenosis significantly increased from 0.39% in 2011 to 4.16% in 2014 (P less then 0.001), which represents a 3.77% overall growth in procedure rate. The median length of stay decreased significantly throughout the study period (mean 12.2 ± 8.2 days to 7.1 ± 5.9 days, P less then 0.001). There was no statistically significant difference between SAVR and TAVR groups in the
Me gusta
Comentario
Compartir
